Skip to content

Predictive Model for Prognosis of Chronic HBV Infection Mothers

Predictive Model for Prognosis of E Antigen-positive Mothers With Chronic HBV Infection: A Multicenter Cohort Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04805034
Acronym
PMFPOEPMWCHI
Enrollment
1600
Registered
2021-03-18
Start date
2021-04-16
Completion date
2024-01-31
Last updated
2021-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B, Chronic

Brief summary

Pregnancy is a complex and coordinated physiological process. Pregnancy and the postpartum period are associated with unique changes in the immune system that may impact the natural history of autoimmune diseases and immune-mediated infections. In the postpartum period. ALT flares have been reported in 20%-60% of untreated women and were more likely to occur in hepatitis B e antigen (HBeAg)-positive patients. It has been postulated that postpartum ALT flares may arise to rapid immune restitution against hepatitis B virus (HBV) antigens in the liver, when may be a timing of antiviral treatment. A large number of previous studies have focused on studies on the interruption of mother-to-child transmission in women with chronic hepatitis B(CHB), but studies on the prognosis of mothers undergoing pregnancy and delivery are very limited. What are the factors that affect the clearance of HBeAg or HBsAg? What kind of antiviral treatment protocol should be adopted for mothers with CHB? It is not only a problem that needs to be solved urgently in clinical practice, but also can provide some clues for understanding the occurrence and development of HBV infection in women of childbearing age. Overall, this study intends to carry out a multi-center two-way cohort study on E antigen-positive CHB women in 9 hospitals in Shaanxi Province. To observe the dynamic changes of virological parameters in these patients, figure out the factors of the serum HBsAg loss and HBeAg seroconversion, and establish relevant predictive models.

Interventions

OTHERAge, BMI,Baseline HBV DNA, Baseline HBeAg level, Baseline HBsAg level, Antiviral treatment, Serum ALT level

Exposure factors: Age, BMI, Family history, Baseline HBV DNA, Baseline HBeAg level, Baseline HBsAg level, Antiviral treatment, Serum ALT level

Sponsors

the Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine
CollaboratorUNKNOWN
Northwest Women's and Children's Hospital, Xi'an, Shaanxi
CollaboratorOTHER
Shaanxi Provincial People's Hospital
CollaboratorOTHER
Baoji Maternal and Child Health Hospital
CollaboratorUNKNOWN
Weinan Central Hospital
CollaboratorOTHER
Ankang Central Hospital
CollaboratorOTHER
Hanzhong Central Hospital
CollaboratorOTHER
Yan'an University Affiliated Hospital
CollaboratorOTHER
First Affiliated Hospital Xi'an Jiaotong University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Age 20-45 years old * Serum HBsAg positive\> 6 months * HBeAg positive at delivery * Good compliance

Exclusion criteria

* Women who give birth to stillbirth due to various reasons * Coinfection with HIV,HCV, syphilis or other sexually transmitted diseases * Severe kidney, cardiovascular, lung, nervous system or immune system diseases * Who are taking immunotherapy drugs or anti-tumor drugs

Design outcomes

Primary

MeasureTime frame
the rate of HBeAg lossPostpartum 96weeks
the rate of HBeAg seroconversionPostpartum 96weeks
the rate of HBsAg lossPostpartum 96weeks

Secondary

MeasureTime frame
the rate of undetectable HBV DNAPostpartum 96weeks
the rate ALT normalizationPostpartum 96weeks
Dynamic changes of serum HBsAg, HBeAg, HBV DNA and HBV RNA titerat delivery, 12 weeks, 24 weeks, 48 weeks, 72 weeks, 96 weeks after delivery

Countries

China

Contacts

Primary ContactTianyan Chen, phD
chentianyan@126.com0086-18991232530
Backup ContactNaijuan Yao, phD
897402048@qq.com0086-13186036653

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026